Wednesday, 8 July 2020

DPT vaccine Market 2019 Market Challenge, Driver, Trends & Forecast To 2025

Market Research Future published a Half – Cooked research report on “Global DPT vaccine Market Research Report – Forecast to 2027” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2027.                                                                                                         
Global Diphtheria Tetanus and Pertussis (DPT) vaccine Market - Overview
The Global Diphtheria Tetanus and Pertussis Vaccine (DPT) vaccine Market is growing exponentially owing to rising prevalence of chronic disease and increasing usage of combination vaccine and therapy are the major factor driving the DPT vaccine Market. Globally the market for DPT vaccine market is expected to grow at the rate of about 7.3% CAGR from 2016 to 2027.
There is an increase in demand of diphtheria tetanus and pertussis vaccine across the globe and rising awareness regarding prevention of diphtheria, tetanus, and pertussis is major factors which are responsible for the growth of this market. The market is expected to show large opportunities in the coming future with the advancement of technology in developing countries and new products with increased accuracy.
Diverging product markets can be seen in preferences for traditional vaccines such as DTP. According to WHO, developed countries prefer to purchase a component of the DPT vaccines such as procure acellular pertussis (DTaP), while most developing countries purchase vaccines with whole cell pertussis (DTwP) components.
However, some of the challenges which the market is expected to face includes competition from new entrants or big pharmaceutical giants entering the business or market and the continuous advancements in the product. Furthermore there are some hindering factors which are restricting the market growth such as side effects and complications during inhalation, high prices of devices, and lack of accuracy etc.
Global DPT vaccine Market - Regional Analysis
Globally, DPT Vaccine market consists of four regions North America, Europe, Asia-Pacific and Middle East and Africa.  North America is the largest market for diphtheria tetanus and pertussis vaccine (DPT) vaccine.
The North American market for DPT Vaccine is expected to grow steadily over the forecasted period. This is due to the presence of high concentration of major market players in North America and its emphasis on vaccination against DPT. North American market consists of countries like the U.S., Canada and Mexico. Death rate sue communicable disease is seen to be growing, thus highlighting the importance of immunization. For instance, In March 2015 U.S FDA approved the use of Quadracel for immunization of children from 4 to 6 years of age. This was a great achievement for Sanofi helping it to maintain its leading position in the market.
Europe is the second-largest market for DPT Vaccine which is expected to grow at an overwhelming CAGR during the forecast period. This is due to increasing research and development activities by pharmaceutical companies and research institutes. The market is growing continuously in Europe as the key market players invested huge financial resources on research and development activities for the production of effective vaccines.  Increasing awareness about immunization of children against Diphtheria, tetanus and pertussis also drive this market in Europe.
Moreover, Asia Pacific is expected to be the fastest growing market for DPT Vaccine market. India is expected to be the emerging and fastest growing market. Presence of large patient pool drive this market in Asia-pacific. This region is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. Governments in developing countries of Asia-Pacific have undertaken various vaccinations programs. National Health Mission in India provide vaccination against diphtheria, pertussis, tetanus and polio.
The market shows steady growth in Middle East and Africa. In Middle East and Africa the demand for DPT vaccine is less than other regions across the globe.
Global DPT vaccine Market - Company Analysis
Merck: Merck provides a wide range of vaccines which includes BCG USP, Pneumonix, Varivax, Pedvax HIB, Recombivax HB and others.
Sanofi: Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, consumer healthcare, established prescription products and generics. Diphtheria and Tetanus Toxoids and acellular Pertussis Vaccine called Daptacel is the product offered by Sanofi which is the major market player.
Merck & Co., Inc (U.S), Sanofi (France), GSK (U.S), Lanzhou Institute of Biological Products (China), Wyeth (U.S), Chiron Pharmaceutical Pvt Ltd (India), Serum Institute of India Pvt. Ltd. (India), Lanzhou Institute of Biological Products (China) and others are some of the prominent players at the forefront of competition in the Global DPT vaccine Market and are profiled in MRFR Analysis. 
Posted by at No comments:

Biosimilars Market, Segments, Growth And Value Chain Analysis 2019

Competitive Analysis
Market Research Future published a Half Cooked research report on “Global Biosimilars Market Research Report - Forecast till 2023”  – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.
Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Sandoz International GmbH (Germany), Celltrion, Inc. (South Korea), Astra Zeneca (UK),  Amgen Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Biocon Ltd. (India), Dr. Reddy’s Laboratories Ltd. (India), Novartis (Switzerland), Accord Healthcare (UK), Eli Lilly (US) and Samsung Bioepis (South Korea) are some of the leading players at the cutting edge of the competition in the market of biosimilars, globally.
Biosimilars is a biological medical product which are identical copy of the original medical product manufacture by different companies. Biosimilars product is the fastest growing market in the United States owing to increasing interest of manufacturer for in this market. It is an approved process and normally manufactured when the original product's patent expires. According to Food and Drug Administration, in 2015, FDA approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA.
Global Biosimilars Market – Overview
The global biosimilars market is rising with a swift phase; mainly owing to enhanced productivity and clinical trial activities for biosimilars and increasing demand for the cheap medical products. There are many recently development due to the expiry of patient of original drugs. In 2015, The U.S. Food and Drug Administration approved Erelzi, (etanercept-szzs) for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998 and in 2016, FDA approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.
Companies are continuously invent new products to capture the market globally. Thus major players invest more in research and development activity, in order to lead the global market. In this regards, Pfizer Inc., in 2016 announced that it has acquired Bamboo Therapeutics, Inc., in order to lead the market. This acquisition combines the technology and research & development and enhance potentially life-changing therapies. PF-05280014, PF-05280586 and PF-06410293 are under biosimilars clinical trials. It is third largest contributor for biosimilars market. Also In 2016, Teva and Celltrion announce exclusive biosimilar commercial partnership. Teva Pharmaceutical share around 20 % of total global biosimilars market.
Sandoz International GmbH, is the global leader in biosimilars. This company shares 11 % of total global biosimilars market. Increasing need of the better treatment and rising investment and funds for research and development have driven the global market. Moreover companies from developed region are majorly focus in export the drugs to emerging market of Asia Pacific region, As countries from these region have more focus to avail effective treatment at reasonable rate.
Global Biosimilars Market   - Regional Analysis
Europe has dominating market for the biosimilars market owing to presence of huge patient population and also major player of Germany, France who have more focused in exporting the drugs to developing region of Asia Pacific. Furthermore Increasing prevalence of diseases and rising geriatric population has led to grow this market in Europe.
Recently in 2017, The U.S. Food and Drug Administration approved first biosimilar for the treatment of cancer, Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer.
The Americas has second leading market for biosimilars players, owing to present of huge population affected with disease. According to Centers for Disease Control and Prevention (CDC), in 2014, seven of the top ten causes of death were chronic diseases that are heart disease and cancer. The main causes for these diseases are smoking and alcohol, whereas report published by Centers for Disease Control and Prevention (CDC) suggest, around 36.5 million adults in the United States said they currently smoked cigarettes, cigarette smoking accounts for more than 480,000 deaths each year.
Asia Pacific and the Middle East and Africa region are considering the huge market. Whereas country like India and china of Asia Pacific region are considering fastest growing region due to presence of huge population effected with chronic disease, additionally they are open to adopt drugs at lower cost. Japan is well developed country and have well established healthcare system and technology, whereas developing countries are still focusing on biosimilars drugs for the treatment, this gap between the developed and developing countries will present significant growth and opportunity for the biosimilars market players to enhance the revenue and biosimilars market share in the coming years.
Posted by at No comments:

Erectile Dysfunction Drugs Market Pipeline Review, 2019- Identify Key Business Opportunities

Competitive Analysis
Market Research Future published a Half Cooked research report on “Global  Erectile Dysfunction Drugs Market Research Report - Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.
Pfizer Inc. (U.S), Bayer AG (Germany), Eli Lily & Co. (U.S), Dong–A Pharmaceutical Co. Ltd. (South Korea), Apricus Biosciences Inc.(U.S), S.K. Chemicals Co. Ltd. (South Korea), Apricus Biosciences Inc. (U.S), Cristalia Produtos Quimicos Farmaceuticos Ltd. (Brazil), Dong-A Pharmaceutical Co. Ltd., (South Korea), Meda Pharmaceuticals, Inc. (U.S),  Vivus, Inc. (U.S),  and others are some of the prominent players at the forefront of competition in the global erectile dysfunction drugs market and are profiled in MRFR Analysis. 
Browse Sample of the Report @   https://www.marketresearchfuture.com/sample_request/1313 
Global Erectile Dysfunction Drugs Market - Overview
Erectile dysfunction is the inability to attain or maintain penile erection in men, sufficient for successful sexual intercourse. It is also known as impotence. It is a common medical disorder primarily affecting men older than 40 years of age. Growing elderly population, increasing awareness and patient education, elevated inclination towards a sedentary lifestyle, and growing incidence of several genitourinary diseases are some of the factors expected to drive the growth of the global erectile dysfunction drugs market. Management of this disorder includes medical history, sexual history and psychological history of a person. There are number of drugs available for the treatment of erectile dysfunction which include both branded and generic drugs. Over 20 million men all over the world have used or are currently using Viagra to treat erectile dysfunction.
Stress and mental health concerns may worsen the problem of erectile dysfunction. Physical and psychological issues may also cause erectile dysfunction. The market of erectile dysfunction drugs is driven by the number of drugs available in the market and increasing number of men suffering from this disorder. There is also an increase in the competition among the major market players. According to a trials conducted by the American Urological Association (AUA) Consensus Panel on Erectile Dysfunction, 36% to 76% of patients on erectile dysfunction drug were able to achieve intercourse during treatment.
The market for erectile dysfunction drugs is growing rapidly and expected to continue its growth in near future. However, factors such as growing threat from counterfeit drugs, prevalence of STDs in erectile dysfunction drug users, and shrinking insurance coverage for ED treatment will hamper the growth of global erectile dysfunction market. Moreover, patent expiry of number of blockbuster drugs, availability of counterfeit drugs and increasing manufactures of generic drugs in the market may result in the decline of erectile dysfunction drugs market. Global market of erectile dysfunction drugs is expected to reach USD 2.95 billion in 2023 from USD 1.65 billion in 2016 over the forecast period 2017-2023.
The global erectile dysfunction drugs market is expected to grow at a CAGR of 6.5% during the forecast period 2017-2023.
Global Erectile Dysfunction Drugs Market – Regional:
Geographically, the regional market is segmented into America, Europe, Asia Pacific, and the Middle East & Africa.
The Americas account for the major share of the market owing to the presence of patient population, well-developed technology, and high healthcare expenditure. According to University of Wisconsin Hospitals and Clinics Authority, about 5 percent of men that are 40 years old have complete erectile dysfunction, and that number increases to about 15 percent of men at age 70. Mild and moderate erectile dysfunction affects approximately 10 percent of men per decade of life.
Europe holds the major Erectile Dysfunction Drugs Market share, which is majorly contributed by Germany, the U.K., and France. According to the UK Health Centre, 50 percent of men that smoke a pack of cigarettes a day have a higher chance of developing erectile dysfunction. Furthermore, as per a study recently presented at the European Association of Urology showed that erectile dysfunction isn’t being treated very often, with only 25.4 percent of men in the being treated for the condition.
Asia Pacific is the fastest growing market owing to rapidly changing healthcare sector, and the presence of huge opportunities for the development of this market. However, the Middle East & Africa has the least share in the market owing to the presence of poor and slow developing countries, especially, in African region. The Middle East holds the major share of the regional market due to well-developed technology and high spending.
Global Erectile Dysfunction Drugs Market Players:
Pfizer Inc. manufactures Viagra drug for erectile dysfunction treatment. Bayer AG manufactures Levitra drugs for the treatment of erectile dysfunction. Eli Lilly and Company manufactures a drug named Cialis for erectile dysfunction.
For instance, in May 2014, Sanofi and Eli Lilly and Company announced an agreement for regulatory OTC approval of Cialis (tadalafil). Cialis is now available as OTC drug worldwide for the treatment of men with erectile dysfunction (ED).
Posted by at No comments:

Blood Glucose Test Strip Market - Granular Market Report And Review, 2019

Competitive Analysis
There are a number of players operating in this market all over the globe. Now-a-days, there is a significant increase in the number of the company offering blood glucose test strip.  Thus, companies are adopting the new strategies to minimize the competition and increase the market share. Some major companies are trying to focus on new and advanced tests & products to gain the market. Whereas, some are has used the technique of acquisition and collaboration to gain the market. Technological advancements and product development represent attractive strategies adopted by some of the leading players for the market. For instance, Bayer developed CONTOUR NEXT (CN) test strip that can used by both trained laboratory personnel and diabetic patients. This test strip uses a flavin adenine dinucleotide-glucose dehydrogenase (FAD-GDH) enzyme, a proprietary phenothiazine electron mediator and algorithm to minimize errors during the testing process.
Key players profiled in the report are Abbott, Roche Diagnostics, LifeScan, i-SENS, Bayer Diabetes Care, AgaMatrix Inc, Elektronika, Universal Biosensors, Nipro Diagnostics, TaiDoc, Apex Biotechnology Corp, B. Braun, HMD BioMedical Inc., ALL Medicus, SANNUO, Beijing Yicheng Electronics, Betachek National Diagnostics, Shanghai MicroSense, Jiangsu Yuyue, ACON Laboratories, and others.
Latest Industry Updates
Being a competitive market, a number of different manufacturer are focusing on the product launch, and acquisition for the market development. Some of the latest development in the market are-
LifeScan’s OneTouch Verio test strips are based on innovative opposing electrode technology developed by Universal Biosensors. This technology provides instant results of blood glucose levels and does not require calibration. Moreover, the results are unaffected by the presence of unrelated sugars such as maltose and galactose, which interfere with the results in a number of other blood glucose systems.
Global Blood Glucose Test Strip Market – Overview
Blood glucose test strip is a small disposable plastic strip and is an important component of blood glucose meters that monitors and controls diabetes. These strips are impregnated with glucose oxidase, which reacts with glucose present in the blood and indicate of the blood glucose level. The global blood glucose test strip market is expected to reach USD 18.5 billion by 2020, and the market is projected to grow at a CAGR of ~ 6.2 % during the forecast period 2015-2020. The market may experience the growth due to several forces, such as government initiatives, convenience offered by self-blood glucose testing over the traditional methods, support and incentives by the governments and healthcare organizations etc. The rising diabetic population is another major driver of the market and one of the major concerns for the government across the globe. According to International Diabetic Federation, about 415 million people had diabetes in 2015, and this number is estimated to reach 642 million by 2040.
Poor reimbursement policy for the test strips may hinder the growth of the market over the forecast period. In March 2013, Medicare announced reimbursement cuts for diabetes testing supplies (DTS) up to 72%, which although reduces the healthcare expenditure; but also drastically reduces the number of vendors from which diabetic patients can obtain glucose-testing supplies. This may reduce the market for blood glucose test strip.
During last few decades, there is a significant increase in the number of patients suffering from diabetes, thus, a number of manufacturers are focusing on the introduction of the new and advanced type of devices which are more easy to handle and more cost-effective than the present available devices.
Regional Analysis
Regionally, the global blood glucose test strip market is segmented into: Americas, Europe, Asia Pacific, and the Middle East & Africa.
The Americas holds a significant market share of the global market owing to extensive use of information technology and high expenditure on the health care. Additionally, the fastest uptake of new technology and the presence & concentration of medical device manufacturers in the US regions drive the blood glucose test strip market. Europe is the second largest market in the globe due to a high healthcare expenditure, which is led by Germany and France. Asia Pacific region is expected to grow rapidly; China and India are likely to lead the market due to unmet needs during the forecasted period. Gulf nations such as Saudi Arabia and the UAE drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic & political conditions and poor healthcare development.
Posted by at No comments:

Clinical Nutrition Market Growth And Restrain Factors Analysis By 2025

Market Research Future published a Cooked  research report on “Global Clinical nutrition Market Report - Forecast to 2027” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2027.
 Clinical Nutrition Market-Overview
Clinical nutrition mainly focuses on the development of nutritional products especially for the patients suffering from chronic diseases such as diabetes, chronic obstructive pulmonary disease, gastrointestinal disorders, cancer, immune system disorders, liver and kidney diseases, and many more. Rising prevalence of chronic diseases, extensive demand for clinical nutrition therapy, and growing awareness about the use of nutritional products drive the growth of the market. Additionally, the prevalence of lifestyle diseases such as obesity, and addiction to smoking and alcohol also stimulate the market growth. The market is expected to show flourishing growth in developing regions of Asia Pacific owing to a rising economic burden of chronic diseases and increasing demand for nutritional supplements. Clinical nutrition is now becoming an important field of interest, due to increase important of nutrition to be provided to the patient during his/her stay at the hospital as well as at home. Quality of products offered by the company determines the quality goals and efficiency that can be achieved so as to attract more and more customers, and increase in the sale of nutritional products. The products are needed to be manufactured through quality assurance and quality control market, thus sustaining the position in the market. Therefore, the company should strive to develop qualitative products to attract more and more customers, and enhance its growth.
Key players in the Clinical Nutrition Market:
Abbott (U.S.), AYMES Nutrition International Ltd. (U.K), NeoMed (U.S.), Baxter International (U.S.), Danone (France), B. Braun Melsungen AG (Germany), Mead Johnson & Company, LLC. (U.S.), Nestlé Health Science (Switzerland), Nutricia Advanced  Clinical nutrition (Netherland), Primus Pharmaceuticals (U.S.), Inc., Solace Nutrition (U.K) and others. The major players focus on the development of products useful for particular segment such as nutritional products for adults, children and geriatric population. The major players focus on the development of products useful for particular segment such as nutritional products for adults, children and geriatric population.
Key Developments:
Strategic approaches adopted help the major players in the market to sustain their growth and develop their business in various geographical areas across the globe. Agreements and collaborations, mergers and acquisitions, and new product launches are various strategies followed by the key players. This help the companies to reach untapped markets in developing nations of the worlds, thus reducing the supply demand gap. The companies develop number of nutritional products for patients, addressing their according to the disease condition. 
Danone:
  • Danone is a French multinational food-products company in France. The company introduced, SYNEO which is the first and only hypoallergenic formula containing prebiotics as well as probiotics for the infants suffering from cow’s milk allergy, multiple food allergies, and related gastrointestinal conditions.
Nestlé Health Science:
  • In October, 2015, Nestlé Health Science has announced its collaboration with GE Healthcare to improve nutrition monitoring for critically-ill patients. RESOURCE, BOOST, PRONOURISH are some of the major product of the company.
  • Nestlé Health Science has acquired Vitaflo headquartered in UK to establish a foothold in the fast-growing market for uniquely formulated products. It has 2nd largest market in US and 1st in Canada.
  • In 2015, Nestlé Health Science acquired Phagenesis, a UK-based company developing Phagenyx, an innovative pharyngeal electrical stimulation device to treat dysphagia.
  • In July, 2015: Nestlé Health Science signed with Seres Therapeutics’ novel class of microbiome therapeutics (Ecobiotics) an exclusive agreement outside the United States and Canada for in the fields of Clostridium difficile infections and Inflammatory Bowel Disease (IBD).
Abbott Nutrition:
  • Abbott manufactures, and sales enormous clinical nutrition products for adult, infant & new mother, infant & new mother, sports & active living, and therapeutic use. The company supplies these nutrition products under various brand names such as Similac, PediaSure, Pedialyte, Ensure, ZonePerfec, EAS, and Glucerna. The company focuses on healthy diabetes, malnutrition, and heart health.
  • June, 2016: Abbott launched new EAS Protein Shakes, Powders and Bars especially for the Athletes with an aim of fuelling their Lifestyles, improving strength, and enhance their performance. The company strives to provide clinically proven nutrition for health-conscious individuals and athletes at every stage of their development, from beginner to professional.
  • April, 2016: Abbott Launched EAS Myoplex Sports Nutrition Line for designed for performance. The product form new line are Myoplex Pre-Workout, Myoplex BCAA + Electrolytes, Myoplex Protein Blend, and Myoplex Micellar Casein.
Research in Clinical Nutrition by Key Players:
Abbott:  A research carried out by University of Illinois and Abbott at the Centre for Nutrition, Learning and Memory discovered that children with higher lutein levels in the eye tend to do better on tests of cognition and academic achievement. This help Abbot to understand the role of nutrition on childhood cognition, which will further help the company to develop product providing maximum benefits children enhancing their cognitive abilities.
Therefore, the market is driven by availability of numerous nutritional products, strategic approaches, and geographical expansion by key players. 
Posted by at No comments:

4D Printing in Healthcare Market Segments, Opportunity, Growth And Forecast By End-Use Industry 2019

Market Overview
Global 4D Printing in Healthcare Market size is expected to register a CAGR of 29.4% during the forecast period from 2019 to 2025 and expected to reach USD 30.4 Million by 2025.
In the past decade, there has been increasing use of 3D printing in the field of healthcare. The introduction of 4D printing and its shape-changing material property in the field of dentistry, implants, and prosthetics, among others will further enhance the 3D products used for these applications. The shape-changing property of the material used for 4D printing has been one of the major factors influencing the growth of the market.
Moreover, factors such as increasing research and development, rising investment by chemical companies. These chemical companies are keen on grabbing the opportunity for the development of smart materials in 4D printing, which in turn is directly enhancing the growth of the market.
Factors such as stringent regulatory policies for the approval of 4D printing medical devices market trends and limited skilled professionals have been major challenges for 4D printing in the healthcare market.  
Market Drivers
  • Increasing application of 4D printing in healthcare verticals such as dentistry, implants, and prosthetics.
    • The dental industry is one of the major applications of 4D printing. Clear aligners have been the most manufactured products via 3D printing in the dental industry.
    • Align technology, the leader in global clear aligners market, accounts for about 80% of the market. The company uses 3D Systems to produce over 1.6 million custom aligners per week.
    • Clear aligners can further be enhanced using 4D printing, as these products require shape altering properties according to the changing structure of the teeth on a weekly basis.
    • 4D printers are also used to manufacture various dental implants, including dental implants, dentures, crowns, & bridges, among others.
    • Increasing prevalence of dental diseases is further influencing the growth of the market. According to the MRFR research study in 2018, it was estimated that oral diseases affected more than 3.7 billion individuals that are around half of the world’s population.
  • Rising research and development
    • A research team from the US in March 2019, invented a new bio-ink that allows to print catalytically active live cells into several self-sustaining 3D geometries. These properties include tunable cell densities, fine filament thickness, and high catalytic productivity.
  • Growing investment by chemical companies
    • Various companies such as BASF Venture Capital GmbH and Evonik Venture Capital have invested in Chinese 3D printing companies
Market Challenges
  • Stringent regulatory policies for the approval of 4D printing medical devices
  • Limited skilled professionals
Segmentation
By Component
  • Software & Services: Software and services accounted for the major market share in 2018. 3D printers have already been installed in numerous healthcare facilities across the globe. However, these machines would require updated software and also various services for the manufacturing of 4D products.
  • Smart Material: Smart Material segment is expected to grow at the fastest growth rate due to continuous advancements for the materials in 4D printing. Investment by chemical companies for the development of smart material is further influencing the market growth.
By Technology
  • Fused Deposition Modeling: Accounted for the largest market share due to its wide choice of raw materials and cost-effective process
  • Direct Inkjet Cure: Expected to grow at the fastest growth rate majorly due to its dimensional accuracy, multi-material, and full-color printing properties
By Application
  • Dental: accounted for the largest market share owing to the use of 4D printing for manufacturing of wide dental products including clear aligners, implants, and dentures among others
  • Prosthetics: Expected to grow at the fastest growth rate due to increasing number of prosthetic procedures, accidental injuries, and sports injuries among others
By End-User
  • Hospitals & Surgical Centers: Accounted for the leading market share owing to the increasing number of hospital & surgical centers. According to a study published by the American Hospital Association, there were 5,534 registered hospitals in the US in 2017.
  • Dental Clinics & Laboratories (Offices): Use of 4D printing in dental clinics & laboratories, brings less complexity to existing procedures. Dental laboratories use 4D printing technologies that allow them to increase competitiveness and production, thus driving the growth of this segment.
By Region
  • Americas: The Americas spearheaded the market in 2018 and is likely to continue to command during the assessment period. This is attributed to the existence of a large number of medical device companies, increasing research and development, and the presence of a large number of noticeable players engaged in manufacturing of 4D printing devices and software
  • Europe: Reported for the second-largest share owing to increasing utilization of 3D & 4D printing in the field of healthcare. According to a study conducted in 2018, it was found that 65% of healthcare providers are implementing new printing technologies for medical products using custom made materials
  • Asia-Pacific: The highest growth rate is attributed to the growing investment by government bodies and private & public companies. For instance, in November 2018, BASF Venture Capital GmbH invested in Chinese 3D printing company Prismlab.
Key Development
  • In January 2019, Dentsply Sirona and Carbon announced a strategic collaboration to revolutionize digital denture materials. This strategic collaboration was announced to deliver denture materials for carbon digital 3D printing production solutions.
Key Players
  • Stratasys Ltd (US)
  • 3D Systems, Inc (US)
  • EnvisionTEC (Germany)
  • Poietis
  • (France) 
  • Organovo Holdings Inc. (US)
  • Materialise NV (Belgium)
  • Dassault Systèmes (France) 
Posted by at No comments:

Worldwide Meningococcal Vaccines Market 2019 Outlook, Top 10 Industry Players Comprehensive Analysis And Forecast To 2025

Market Forecast
Meningococcal Vaccines Market Size has a demand for USD 172 Million doses in 2019. Further, the global estimated supply in 2019 is expected to be 203 Million doses.
Market Synopsis
Meningococcal meningitis is a bacterial infection caused by Neisseria meningitides. Disease incidence is high in West and Central Africa, where historically, serogroup A has been the most important cause of disease. More recently, meningitis outbreaks have gradually been associated with serogroup C, and to a lesser extent, serogroup W.
The meningococcal vaccines market is complex and diverse, with regional variations in serogroup distribution with substantial use outside routine immunization. The vaccine has approximately 29 marketed products targeting various combinations of the six serogroups (A, B, C, W, X, Y).
Market Influencer
Without an increase in production, the existing supply of conjugate MenACWY will be inadequate to meet the demand generated by the rising incidence of serogroups C and W, and the low availability of polysaccharide vaccines. Further, several multivalent, conjugate vaccines by Chinese and Indian manufacturers are in the pipeline, and, if prequalified they will be registered for use in many geographies. Moreover, if they are made available at acceptable prices it could increase global demand in Meningococcal Vaccines Market Trends.
Market Drivers
  • Rise in prevalence of the meningococcal disease
    • According to a document published by the U.S. Department of Health & Human Services, in 2017, there were approximately 350 cases of meningococcal disease reported. The disease has an incidence rate of 0.11 cases per 100,000 people in the United States. Any population group can be affected by the disease, with maximum prevalence in children younger than one-year-old and a second peak in adolescence. Adolescents and young adults, ranging from 16 to 23 years old, have the highest rates of meningococcal disease.
    • Further, increasing incidence of meningococcal disease in West and Central Africa regions is expected to drive the demand in the African region
  • Booming mortality of the meningococcal disease is leading to increasing demand for the vaccines
    • Approximately 10 to 15 in 100 people affected with meningococcal disease will face mortality. Further, up to 1 in 5 survivors will have long-term disabilities, such as loss of limb, deafness, and damage to the nervous system brain among others
  • Escalating positive results with the vaccines to boost the demand in the market
  • Growing research and development activities by prominent players in the industry
Market Restraints
  • Withdrawn production of polysaccharide vaccines has resulted in reduced country access, particularly for MICs in various regions. For example, Sanofi Pasteur, manufacturer of Menomune, declared in 2017 that the company is discontinuing the production of the vaccine. With the production of Menomune at hold, there were no polysaccharide vaccines approved for use in the United States

Meningococcal Vaccines Market Segmentation

By treatment, the market is segmented into Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine.
Meningococcal A conjugate vaccine is significantly used in mass campaigns across affected regions like Africa. Since 2010, the vaccine has significantly decreased meningococcal disease incidence in the region. However, the demand for meningococcal A conjugate in the country remains uncertain given that national immunization program adoptions are based on the timing of Gavi funding decisions, the country’s readiness, and competing for vaccine introduction priorities.
In the polysaccharide segment, products such as MenACWY vaccines are in high demand. MenACWY vaccine is the most desirable combination, given its broader serotype coverage. MenACWY specifically has nine products that are available across polysaccharide and conjugate product segments, but conjugate products are suggested for use in routine immunization activities.
Moreover, the demand and supply of Subcap MenB vaccines is restricted to HICs and influenced by their acceptance into NIPs. Improved uptake of MenB vaccines is expected in the coming years but will likely be moderate and limited to high-income markets given the high price and competing interest of introducing MenACWY conjugate.
By end-user, the market is segmented into Hospital & Clinical, Research Laboratories, and Academic Institutes
Hospitals and clinics control the global market for meningococcal vaccines. The high growth of hospitals and clinics segment is attributed to the increasing application of vaccines in these healthcare facilities in conjunction with the growing prevalence and incidence of the meningococcal disease.
Moreover, research laboratories and academic institutes take up the second-largest share due to the boost in research and development in the market.
By region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
In the global market, China is expected to have the largest market share, which accounts for approximately 35% of the global demand. This is primarily due to polysaccharide products, which currently comprise 84% of China’s demand. Chinese suppliers presently focus only on meeting the demand of the domestic market, but some of the manufacturers have indicated interest in the global market as well. The dynamic product pipeline with several multivalent conjugate products in development may trigger changes in the future supply mix of the Chinese market. Moreover, in China, non-routine use (excluding campaigns) accounts for an estimated 9 million doses in 2019, which may help to sustain the huge market share in the forecast period.
UNICEF foresees all 26 African countries in the meningitis belt, which have completed mass campaigns in 2016. In 2015, seven countries in the region were introduced with meningococcal A conjugate vaccine through their mass campaigns and targeted a population of 233 million. Further, during 2016-2018, UNICEF introduced meningococcal A conjugate vaccine in 26 countries. Ghana was the first country to be introduced with the vaccine into its RI schedule in 2016. Also, four other countries including Mali, Niger, Nigeria, and Sudan introduced the vaccine into RI programs in 2016.
Key Developments in the Global Meningococcal Vaccines Market
  • In 2018, Pfizer granted FDA Breakthrough Therapy designation for Trumenba (Meningococcal Group B Vaccine). This vaccine plays a major role in the prevention of invasive meningococcal B disease in children aged 1 to 9 years
  • In 2018, GSK’s meningitis B vaccine Bexsero received Breakthrough Therapy designation from the US FDA for prevention of Invasive Meningococcal Disease for children 2-10 years of age
  • In 2015, Novartis Bexsero vaccine was approved by the FDA for the prevention of meningitis B. This vaccine is used as active immunization to prevent invasive meningococcal disease caused by serogroup B
Key Players
  • Baxter international
  • Pfizer Inc.
  • Sanofi S.A.
  • Novartis Pharmaceuticals Inc.
  • JN-International Medical Corporation
  • Serum Institute of India Ltd.
  • GlaxoSmithKline
  • BIO-MED
  • Others
Posted by at No comments:
Subscribe to: Posts (Atom)